| Recruiting | Platform Trial For Cryptococcal Meningitis NCT06666322 | University of Minnesota | Phase 2 / Phase 3 |
| Completed | Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis NCT06414512 | University of Minnesota | Phase 2 |
| Enrolling By Invitation | Amphotericin B for Non-HIV Cryptococcal Meningitis Patients NCT06178627 | Huashan Hospital | Phase 4 |
| Unknown | Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City NCT05685641 | National Institute of Respiratory Diseases, Mexico | N/A |
| Unknown | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 NCT05541107 | Matinas BioPharma Nanotechnologies, Inc. | Phase 3 |
| Unknown | Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis NCT05471063 | Peking Union Medical College Hospital | N/A |
| Unknown | Three Induction Treatments on Cryptococcal Meningitis NCT04072640 | First Affiliated Hospital of Zhejiang University | EARLY_Phase 1 |
| Completed | Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meni NCT04532463 | University of Pharmacy, Yangon | — |
| Completed | The Lived Experience of Participants in an African Randomised Trial NCT04296292 | London School of Hygiene and Tropical Medicine | — |
| Unknown | AmB Dose for Cryptococcal Meningitis NCT04140461 | Shanghai Public Health Clinical Center | Phase 3 |
| Completed | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) NCT04031833 | Matinas BioPharma Nanotechnologies, Inc. | Phase 1 / Phase 2 |
| Recruiting | Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia NCT03945448 | Makerere University | Phase 2 / Phase 3 |
| Completed | Driving Reduced AIDS-associated Meningo-encephalitis Mortality NCT03226379 | St George's, University of London | N/A |
| Unknown | Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis NCT02686853 | Hui Bu | Phase 4 |
| Unknown | Vietnam Cryptococcal Retention in Care Study - Version 2.1 NCT03267407 | National Hospital for Tropical Diseases, Hanoi, Vietnam | — |
| Unknown | Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS NCT02624453 | ANRS, Emerging Infectious Diseases | N/A |
| Completed | Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report NCT02955862 | National Hospital for Tropical Diseases, Hanoi, Vietnam | Phase 1 |
| Completed | CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Afri NCT02434172 | University of Zimbabwe | — |
| Completed | Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis NCT01802385 | University of Minnesota | Phase 3 |
| Completed | Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy NCT02098525 | Mahidol University | — |
| Completed | Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DR NCT01589289 | Institute of Tropical Medicine, Belgium | Phase 3 |
| Completed | Operational Research for Cryptococcal Antigen Screening NCT01535469 | University of Minnesota | Phase 4 |
| Unknown | Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Th NCT01715922 | ANRS, Emerging Infectious Diseases | Phase 2 / Phase 3 |
| Unknown | Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis NCT02136030 | TTY Biopharm | N/A |
| Completed | Cryptococcal Optimal ART Timing Trial NCT01075152 | University of Minnesota | Phase 4 |
| Completed | High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals NCT00885703 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis NCT00976040 | Botswana-UPenn Partnership | Phase 4 |
| Recruiting | Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia NCT00867269 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Terminated | Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS NCT00324025 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa NCT00830856 | University of Zimbabwe | N/A |
| Terminated | Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS NCT00847678 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis NCT00145249 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Fungal Infection Susceptibility NCT00001352 | National Institute of Allergy and Infectious Diseases (NIAID) | — |